Bris­tol My­ers joins As­traZeneca in agree­ing to drug price ne­go­ti­a­tion terms ahead of first dead­line

Phar­ma com­pa­nies are now re­luc­tant­ly agree­ing to par­tic­i­pate in the Cen­ter for Medicare and Med­ic­aid Ser­vices’ first round of ne­go­ti­a­tions for 10 drugs.

Ahead of a key Oct. 1 dead­line, both Bris­tol My­ers Squibb and As­traZeneca have now said they will par­tic­i­pate in the ne­go­ti­a­tions with CMS, al­though near­ly all of the com­pa­nies on the ini­tial list have in­sist­ed the ne­go­ti­a­tions are more akin to price con­trols.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.